

Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	Phase I	Phase II	Sponsor / Licensee
<b>PDAC</b> CRC, GBM, Ewing Sarcoma, Melanoma	<i>Neurotensin Receptor</i> (NTR)	IPN-01087 3BP-227							
<b>FAP Expressing Tumors</b>	<i>Fibroblast Activation Protein</i> (FAP)	FAP-2286							 Europe  US, RoW
<b>Neuroendocrine Tumors</b>	<i>Gastric Inhibitory Polypeptide Receptor</i> (GIP-R)	3B-401 3B-402							
<b>CAIX Expressing Tumors</b>	<i>Carbonic Anhydrase IX</i> (CAIX)	Debio 0228							
<b>Solid Tumors</b>	<i>Undisclosed</i>	NTA							
<b>Solid Tumors</b>	<i>Undisclosed</i>	NTB							
<b>Solid Tumors</b>	<i>Undisclosed</i>	NTC							
<b>Solid Tumors</b>	<i>Undisclosed</i>	3BP							
<b>Solid Tumors</b>	<i>Undisclosed</i>	3BP							
<b>Solid Tumors</b>	<i>Undisclosed</i>	3BP							

THERAPEUTIC RADIOPHARMACEUTICAL  
 SPECT OR PET IMAGING AGENT